Migraine day frequency in migraine prevention: longitudinal modelling approaches.

ABSTRACT:

Background

Health economic models are critical tools to inform reimbursement agencies on health care interventions. Many clinical trials report outcomes using the frequency of an event over a set period of time, for example, the primary efficacy outcome in most clinical trials of migraine prevention is mean change in the frequency of migraine days (MDs) per 28 days (monthly MDs [MMD]) relative to baseline for active treatment versus placebo. Using these cohort-level endpoints in economic models, accounting for variation among patients is challenging. In this analysis, parametric models of change in MMD for migraine preventives were assessed using data from erenumab clinical studies.

Methods

MMD observations from the double-blind phases of two studies of erenumab were used: o

SUBMITTER: Di Tanna GL 

PROVIDER: S-EPMC6343253 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature